Adults patients will be included in the hematology departments. Eligible patients will be those scheduled to receive an allo-HSC after a RIC conditioning regimen for a myeloid or lymphoid hematological malignancy with a family or non-family HLA-matched donor 10/10

• Randomized Phase 2 study testing two conditioning regimen with a single prophylaxis of graft-versus-host disease by cyclophosphamide and met … Recruiting
  2023-509042-35-01 4 2024-07-18

Showing 1–1 of 1 trials